Thr215

Site Information
KREFANFtFPrLPGk SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 12441091
Available spectra: 1 CST

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 )
Disease tissue studied:	luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, triple negative ( 1 ) , lung cancer ( 4 , 5 , 6 ) , non-small cell lung cancer ( 5 , 6 ) , non-small cell lung adenocarcinoma ( 5 , 6 ) , non-small cell large cell lung carcinoma ( 6 ) , small-cell lung cancer ( 4 ) , melanoma skin cancer ( 2 )
Relevant cell line - cell type - tissue:	A549 (pulmonary) ( 5 ) , breast ( 1 ) , DMS79 (pulmonary) ( 4 ) , Jurkat (T lymphocyte) ( 7 ) , liver ( 3 ) , lung ( 4 , 5 , 6 ) , NCI-H128 (pulmonary) ( 4 ) , NCI-H1299 (pulmonary) ( 6 ) , NCI-H1355 (pulmonary) ( 5 ) , NCI-H1417 (pulmonary) ( 4 ) , NCI-H1734 (pulmonary) ( 6 ) , NCI-H1792 (pulmonary) ( 5 ) , NCI-H1944 (pulmonary) ( 6 ) , NCI-H209 (pulmonary) ( 4 ) , NCI-H23 (pulmonary) ( 5 ) , NCI-H358 (pulmonary) ( 6 ) , NCI-H441 (pulmonary) ( 5 ) , NCI-H460 (pulmonary) ( 6 ) , NCI-H524 (pulmonary) ( 4 ) , WM239A (melanocyte) ( 2 )

References
1	Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 27251275 Curated Info
2	Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615 25850435 Curated Info
3	Bian Y, et al. (2014) An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome. J Proteomics 96, 253-62 24275569 Curated Info
4	Rikova K, Hall B (2013) CST Curation Set: 20734, 21161, 30112, 30153, 30154; Year: 2013; Biosample/Treatment: cell line, H1417, DMS79, H128, H209, H524; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
5	Rikova K, Hall B (2013) CST Curation Set: 20736, 21163, 30158, 30159, 30160; Year: 2013; Biosample/Treatment: cell line, A549, H1355, H23, H441, H1792; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
6	Rikova K, Hall B (2013) CST Curation Set: 20737, 21164, 30161, 30162, 30163; Year: 2013; Biosample/Treatment: cell line, H1299, H1944, H358, H1734, H460; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
7	Guo A (2011) CST Curation Set: 12058; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pTXR Curated Info